Clinical Trial Update: AS703569 and Gemcitabine Combination in Advanced Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial of AS703569 in combination with gemcitabine in pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• AS703569 (AS703569)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Pancreatic Cancer | Phase 1 | Status: COMPLETED